<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2885">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327388</url>
  </required_header>
  <id_info>
    <org_study_id>EFC16844</org_study_id>
    <secondary_id>2020-001162-12</secondary_id>
    <nct_id>NCT04327388</nct_id>
  </id_info>
  <brief_title>Sarilumab COVID-19</brief_title>
  <official_title>An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients
      hospitalized with severe or critical COVID-19

      Secondary Objectives:

        -  Evaluate the 28-day survival rate

        -  Evaluate the clinical efficacy of sarilumab compared to the control arm by clinical
           severity

        -  Evaluate changes in the National Early Warning Score 2 (NEWS2)

        -  Evaluate the duration of predefined symptoms and signs (if applicable)

        -  Evaluate the duration of supplemental oxygen dependency (if applicable)

        -  Evaluate the incidence of new mechanical ventilation use during the study

        -  Evaluate the duration of new mechanical ventilation use during the Study

        -  Evaluate the proportion of patients requiring rescue medication during the 28-day period

        -  Evaluate need for admission into intensive care unit (ICU)

        -  Evaluate duration of hospitalization (days)

        -  The secondary safety objectives of the study are to evaluate the safety of sarilumab
           through hospitalization (up to day 29 if patient is still hospitalized) compared to the
           control arm as assessed by incidence of:

             -  Serious adverse events (SAEs)

             -  Major or opportunistic bacterial or fungal infections in patients with grade 4
                neutropenia

             -  Grade ≥2 infusion related reactions

             -  Grade ≥2 hypersensitivity reactions

             -  Increase in alanine transaminase (ALT) ≥3X upper limit of normal (ULN) (for
                patients with normal baseline) or &gt;3X ULN AND at least 2-fold increase from
                baseline value (for patients with abnormal baseline)

             -  Major or opportunistic bacterial or fungal infections
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An individual patient will complete the study approximately 60 days from screening to
      follow-up on day 60 ±7 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2020</start_date>
  <completion_date type="Actual">September 2, 2020</completion_date>
  <primary_completion_date type="Actual">July 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to improvement of 2 points in clinical status assessment from baseline using the 7-point ordinal scale</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>The ordinal scale is an assessment of the clinical status. Score ranges 1-7. Lower score is worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of patients alive at Day 29</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with one point improvement from baseline in clinical status assessment at days 4, 7, 15, 21, 29 using the 7-point ordinal scale</measure>
    <time_frame>Baseline to Days 4, 7, 15, 21, 29</time_frame>
    <description>The ordinal scale is an assessment of the clinical status. Score ranges 1-7. Lower score is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the 7-point ordinal scale from baseline to Days 4, 7, 15, 21, and 29 (or until discharge)</measure>
    <time_frame>Baseline to Days 4, 7, 15, 21, 29 (or until discharge)</time_frame>
    <description>The ordinal scale is an assessment of the clinical status. Score ranges 1-7. Lower score is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Defined as body temperature (≤36.6°C [axilla], or ≤37.2 °C [oral], or ≤37.8°C [rectal or tympanic]) for at least 48 hours without antipyretics or until discharge, whichever is sooner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution of fever and improvement in oxygenation</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Resolution of both fever and improvement in oxygenation. Resolution of fever is defined as body temperature (≤36.6°C [axilla], or ≤37.2 °C [oral], or ≤37.8°C [rectal or tympanic]) for at least 48 hours without antipyretics or until discharge, whichever is sooner. Improvement in oxygenation is defined as SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2 for at least 48 hours, or until discharge, whichever is sooner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days with fever</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Fever is defined as &gt;37.4°C (axilla), or &gt;38.0 °C (oral), or &gt;38.4°C (rectal or tympanic) based on maximum value observed during a 24-hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to change in NEWS2 from baseline</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>The National Early Warning Score (NEWS2) is used to standardize the assessment of acute-illness severity, track the clinical condition of patients, and to alert clinical teams to patient deterioration. Score ranges from 0-20. A higher score is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to NEWS2 of &lt;2 and maintained for 24 hours</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>The NEWS2 is used to standardize the assessment of acute-illness severity, track the clinical condition of patients, and to alert clinical teams to patient deterioration. Score ranges from 0-20. A higher score is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to days 4, 7, 15, 21, and 29 in NEWS2</measure>
    <time_frame>Baseline to days 4, 7, 15, 21, and 29</time_frame>
    <description>The NEWS2 is used to standardize the assessment of acute-illness severity, track the clinical condition of patients, and to alert clinical teams to patient deterioration. Score ranges from 0-20. A higher score is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-improvement in oxygenation</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>SpO2/FiO2 of 50 or greater compared to the nadir for at least 48 hours, or until discharge, whichever is sooner. SpO2 is oxygen saturation and FiO2 is the fraction of inspired oxygen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alive off supplemental oxygen at day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Supplemental oxygen is defined as oxygen administration by nasal cannula, simple face mask, or other similar oxygen delivery device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of hypoxemia</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Hypoxemia is defined as SpO2 &lt;93% on room air, or requiring supplemental oxygen, or mechanical ventilatory support.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of supplemental oxygen use</measure>
    <time_frame>Baseline to Day 29</time_frame>
    <description>Supplemental oxygen is defined as oxygen administration by nasal cannula, simple face mask, or other similar oxygen delivery device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of resting respiratory rate &gt;24 breaths/min</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to saturation ≥94% on room air</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator free days in the first 28 days (to day 29)</measure>
    <time_frame>Baseline to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients with Initiation of mechanical ventilation, non-invasive ventilation, or use of high flow nasal cannula</measure>
    <time_frame>Baseline to Day 60</time_frame>
    <description>For those not requiring these interventions at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring rescue medication during the 28-day period</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients transferred to the ICU or the need to transfer to the ICU (if the ICU is not available)</measure>
    <time_frame>Baseline to Day 60</time_frame>
    <description>For patients are not in ICU at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of hospitalization among survivors</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of major or opportunistic bacterial or fungal infections</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of major or opportunistic bacterial or fungal infections in patients with grade 4 neutropenia</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of hypersensitivity reactions, infusion reactions, gastrointestinal perforation</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients with clinically significant laboratory abnormalities</measure>
    <time_frame>Baseline to Day 60</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Sarilumab Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab Dose 1 given intravenously one time on Day 1. Patients may receive a second dose with Sarilumab Dose 1 24 to 48 hours after the first dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarilumab Dose 2 given intravenously one time on Day 1. Patients may receive a second dose with Sarilumab Dose 2 24 to 48 hours after the first dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo given intravenously one time on Day 1. Patients may receive a second dose with matching placebo 24 to 48 hours after the first dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarilumab SAR153191</intervention_name>
    <description>Pharmaceutical form:Solution for injection Route of administration: Intravenous infusion</description>
    <arm_group_label>Sarilumab Dose 1</arm_group_label>
    <arm_group_label>Sarilumab Dose 2</arm_group_label>
    <other_name>REGN88</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form:Solution for injection Route of administration: Intravenous infusion</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

        Participants must be ≥18 years of age Participants must be hospitalized for less than or
        equal to 7 days with evidence of pneumonia and have one of the following disease
        categories: severe disease or critical disease Laboratory-confirmed SARS-CoV-2 infection

        Exclusion criteria:

        Unlikely to survive after 48 hours from screening or unlikely to remain at the
        investigational site beyond 48 hours. Patients with multi organ dysfunction or requiring
        extracorporeal life support or renal replacement therapy are excluded.

        Presence of neutropenia less than 2000/mmˆ3, AST or ALT greater than 5 X ULN, platelets
        less than 50,000/mmˆ3 Prior immunosuppressive therapies Use of systemic chronic
        corticosteroids for non-COVID-19 related condition Known or suspected history of
        tuberculosis Suspected or known active systemic bacterial or fungal infections

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 0320001</name>
      <address>
        <city>Caba</city>
        <zip>1430</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0320003</name>
      <address>
        <city>Caba</city>
        <zip>C1180AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0320004</name>
      <address>
        <city>Caba</city>
        <zip>C1426AAM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0760003</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90110-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0760001</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01327-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0760002</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04231-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0760004</name>
      <address>
        <city>São José Do Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0760005</name>
      <address>
        <city>São Paulo</city>
        <zip>04321-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240001</name>
      <address>
        <city>Montreal</city>
        <zip>H2X3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240005</name>
      <address>
        <city>Montreal</city>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240004</name>
      <address>
        <city>Toronto</city>
        <zip>M4N3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240002</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240003</name>
      <address>
        <city>Vancouver</city>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1520003</name>
      <address>
        <city>Santiago</city>
        <zip>750-0691</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1520002</name>
      <address>
        <city>Santiago</city>
        <zip>80004005</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1520004</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1520001</name>
      <address>
        <city>Talca</city>
        <zip>3460001</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500001</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500007</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500006</name>
      <address>
        <city>La Roche Sur Yon Cedex 9</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500002</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500005</name>
      <address>
        <city>Paris Cedex 18</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500003</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2500004</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760002</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760004</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2760001</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site number 3760003</name>
      <address>
        <city>Ashdod</city>
        <zip>7747629</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3760002</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3760001</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52662</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800005</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800001</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800002</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800003</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800004</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800006</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920002</name>
      <address>
        <city>Fuchu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920003</name>
      <address>
        <city>Iruma-Gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3920001</name>
      <address>
        <city>Kamakura-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430003</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430002</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430001</name>
      <address>
        <city>Moscow</city>
        <zip>129301</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240003</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240004</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240002</name>
      <address>
        <city>Madrid / Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240005</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240001</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

